Secondary Malignancies Following CAR T‐Cell Therapy for B‐Cell Malignancies: A Retrospective Analysis
Development of a secondary malignancy is a potential complication following CART therapy. Results of this single-center study should be confirmed with larger multicenter studies. <b>Trial Registration</b>: The authors have confirmed clinical trial registration is not needed for this submission.
Authors
- Tobias Berg (ORCID: https://orcid.org/0000-0003-2668-0449)
- Ronan Foley (ORCID: https://orcid.org/0000-0001-6550-1410)
- Joanne Britto
- Dong An (ORCID: https://orcid.org/0000-0001-5306-2561)
- Amaris Balitsky (ORCID: https://orcid.org/0000-0002-2831-9107)
- Gwynivere A Davies (ORCID: https://orcid.org/0000-0003-4472-6535)
- Graeme Fraser
- Gregory R. Pond (ORCID: https://orcid.org/0000-0003-1033-0882)
- Kylie Lepic (ORCID: https://orcid.org/0000-0002-7287-0924)
- Tom Kouroukis
Institutions
- Juravinski Cancer Centre (CA)
- McMaster University Medical Centre (CA)
- Juravinski Hospital (CA)
- Ontario Clinical Oncology Group (CA)
- McMaster University (CA)
Publication Details
- Journal
- eJHaem
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1002/jha2.70164
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Cancer Research Society
- Leukemia and Lymphoma Society of Canada
- Government of Ontario